Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $19.00

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.00.

Several research firms have recently weighed in on ARTV. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 17th. HC Wainwright raised their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Wedbush increased their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th.

Artiva Biotherapeutics Trading Up 5.8%

Shares of ARTV opened at $3.31 on Friday. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $13.19. The company has a market cap of $81.26 million, a PE ratio of -1.28 and a beta of 3.04. The stock has a 50-day moving average price of $3.46 and a 200-day moving average price of $2.74.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. As a group, analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the completion of the sale, the chief executive officer owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Artiva Biotherapeutics by 26.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock valued at $165,000 after buying an additional 11,355 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $48,000. Nuveen LLC purchased a new position in Artiva Biotherapeutics in the 1st quarter worth approximately $144,000. Ground Swell Capital LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $38,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.